Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Columbia University
Advanced Accelerator Applications
Advanced Accelerator Applications
University of Washington
National Cancer Institute (NCI)
Crinetics Pharmaceuticals Inc.
Hutchmed
Grupo Espanol de Tumores Neuroendocrinos
Hoffmann-La Roche
Grupo Espanol de Tumores Neuroendocrinos
Memorial Sloan Kettering Cancer Center
Hutchmed
Imperial College London
Grupo Espanol de Tumores Neuroendocrinos